MREO News and Press, Mereo BioPharma Group From 02/10/20

Gainers: vTv Therapeutics (NASDAQ: VTVT )  +57% . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...

vTv Therapeutics (NASDAQ: VTVT ) +80%  on positive TTP399 data . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., Edgewell Personal Care Company, Stocks on the move, Read more ...

Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP )  +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...

RTI Surgical Holdings (NASDAQ: RTIX ) +105%  on sale of OEM business . More news on: RTI Surgical Holdings, Inc., TransEnterix, Inc., XBiotech Inc., Stocks on the move, , Read more ...

Thinly traded nano cap Mereo BioPharma Group plc (NASDAQ: MREO ) is up  19%  premarket on modest volume in reaction to additional data from a Phase 2b clinical trial, ASTEROID , evaluating setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta , also known ...

Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Statistical Significance in High Dose Cohort Statistically Significant Increase in Trabec...

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Mereo BioPharma Group ( MREO +27.1% ) is up more than double normal volume, albeit on turnover of only 465K shares, on the heels of its out-licensing agreement with Oncologie for exclusive global rights to ovarian cancer candidate navicixizumab, one of two assets M...

Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56%  as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...

Oncologie receives exclusive global license to develop and commercialize navicixizumab LONDON, and REDWOOD CITY, Calif., and BOSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," and Oncologie, Inc. (“Oncologieȁ...